Company Overview
Purple Biotech Ltd is a clinical-stage biotechnology entity dedicated to developing novel therapies designed to overcome tumor immune evasion and drug resistance for cancer patients in the United States. The company operates within the healthcare sector, specifically focusing on the biotechnology industry, which implies a high degree of scientific innovation and regulatory complexity inherent in drug development. As of the latest available data, the company maintains a market capitalization of $6.12M and employs 10 individuals to support its operations. The combination of a market cap under $10 million and the absence of reported annual revenue indicates that Purple Biotech is a micro-cap entity in the early stages of commercialization or clinical progression. This valuation profile suggests the company is currently valued primarily on the potential of its oncology pipeline rather than established financial performance, positioning it as a high-risk, high-potential asset for investors seeking exposure to early-stage biotechnology innovation.
Financial Health
The company reports a net income loss of $-26,386,000 over the trailing twelve months, while its EBITDA stands at $-6,973,000; the significant gap between these two negative figures reveals a cost structure where non-operating expenses or specific one-time charges are driving a loss that is substantially larger than the operational burn rate. Free cash flow is reported at $-54,000, which indicates a near-neutral position regarding immediate cash consumption, suggesting the company is managing its operational cash outflows efficiently despite the overall net loss. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, indicating that the company has not yet generated positive gross profits or operating earnings, which is typical for clinical-stage firms but highlights a lack of current profitability. The balance sheet shows $9.57M in cash against $244,000 in debt, resulting in a debt-to-equity ratio of 2.53, which presents a complex picture of a cash-rich balance sheet offset by a high leverage ratio relative to equity. The current ratio is 1.27, indicating that the company holds sufficient current assets to cover its current liabilities, though the margin is relatively tight for an entity with negative earnings. Return on Equity is -124.5% and return on assets is -16.0%, metrics that reveal that management effectiveness, as measured by traditional return ratios, is currently negative due to the cumulative losses incurred during the development phase of its therapeutic candidates.
Valuation Assessment
The trailing twelve-month P/E ratio is listed as N/A due to the lack of positive net income, while the forward P/E is calculated at -6.26; the negative forward P/E implies that the market is pricing in an expectation of continued losses or that earnings are projected to remain negative in the near term. The price-to-book ratio is 801.00, a figure that indicates the market is valuing the company at a massive premium over its book value, likely reflecting the high valuation placed on the intellectual property and pipeline potential rather than tangible assets. The price-to-sales ratio is N/A because revenue is not reported, and the EV/EBITDA stands at -1066.34, suggesting that traditional multiple-based valuation models are not applicable given the negative earnings and lack of sales data. The stock has traded between a 52-week low of $3.65 and a 52-week high of $29.40, meaning the current price sits somewhere within this wide range, exhibiting significant historical volatility typical of micro-cap biotechnology stocks. The beta is -0.74, a negative value that indicates the stock's price movements are not only volatile but often inversely correlated with the broader market, presenting a unique risk-return profile distinct from standard equity investments.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, meaning there is no historical data available to determine whether earnings are growing faster or slower than revenue. Because the company has not generated positive revenue, no dividend yield or payout ratio is available, and the payout ratio is recorded as 0.0%, confirming that the company does not distribute dividends to shareholders. Instead of paying dividends, the company operates under a standard biotechnology model where earnings, when positive in the future, would be reinvested into research and development, clinical trials, and pipeline expansion rather than distributed as income. The overall growth and income profile is characterized by a complete absence of current financial metrics, indicating that the company's value is entirely derived from the future potential of its oncology pipeline, including CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen.